GlassScriptPhysician profile
Sarah Lasala
NPI 1205327566
$5,537.69
in general payments reported to CMS, 2019-2025
23 companies · $3,284 in 2025
The $3,284 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $206 · 2024: $2,047 · 2025: $3,284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,222 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,221.89 |
| Education | $109.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $877.13 | 2021-2025 | |
| Ucb, INC. | $586.04 | 2024-2025 | Bimzelx |
| Janssen Biotech, INC. | $494.34 | 2024-2025 | Tremfya |
| Leo Pharma INC. | $489.39 | 2021-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $449.00 | 2024-2025 | |
| Incyte Corporation | $361.92 | 2024-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $361.52 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $306.28 | 2024-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $272.22 | 2024-2025 | Libtayo, Dupixent |
| Lilly USA, LLC | $237.24 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $228.78 | 2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $188.08 | 2024-2025 | Zoryve |
| Genzyme Corporation | $172.08 | 2024-2025 | |
| Amgen INC. | $98.40 | 2021-2025 | Otezla, Otezla |
| Pfizer INC. | $92.99 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $84.89 | 2021-2025 | Cabtreo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.50 | 2024-2025 | Spevigo, Cyltezo |
| Botanix Sb INC | $50.38 | 2025 | Sofdra |
| Genentech USA, INC. | $32.13 | 2024 | Xolair |
| Organon LLC | $30.94 | 2025 | |
| Fresenius Kabi USA, LLC | $28.98 | 2024 | Idacio |
| Verrica Pharmaceuticals INC. | $22.20 | 2025 | Ycanth |
| Lnhc, INC | $14.26 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Lasala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.